Seroprevalence of rubella antibodies in The Netherlands after 32 years of high vaccination coverage

Vaccine

Volumn 32, Issue 16, 2014, Pages 1890-1895

  Smits, Gaby ^a   Mollema, Liesbeth ^a   Hahné, Susan ^a   De Melker, Hester ^a   Tcherniaeva, Irina ^a   Van Der Klis, Fiona ^a   Berbers, Guy ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Antibody levels; Cross sectional population based serosurveillance study; Rubella virus; Seroprevalence

Indexed keywords

RUBELLA ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ETHNICITY; FEMALE; GEOMETRY; GROUPS BY AGE; HERD IMMUNITY; HIGH RISK POPULATION; HUMAN; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NETHERLANDS; PRESCHOOL CHILD; PRIORITY JOURNAL; RELIGIOUS GROUP; RUBELLA; RUBELLA VIRUS; SCHOOL CHILD; SEROPREVALENCE; VACCINATION; YOUNG ADULT;

ANTIBODY LEVELS; CROSS-SECTIONAL POPULATION-BASED SEROSURVEILLANCE STUDY; RUBELLA VIRUS; SEROPREVALENCE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DISEASE OUTBREAKS; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NETHERLANDS; RISK FACTORS; RUBELLA; RUBELLA VACCINE; SEROEPIDEMIOLOGIC STUDIES; VACCINATION; YOUNG ADULT;

EID: 84895862398     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.066     Document Type: Article

References (24)

1. Gregg N.M. Congenital defects associated with maternal rubella. Aust Hosp 1947, 14(11):7-9.
2. Gezondheidsraad Advies inzake Bof-/Rubella-vaccinatie 1984, Staatsuitgeverij, Den Haag.
3. van der Veen J. Vaccination against mumps and rubella, advice of the Health Council. Ned Tijdschr Geneeskd 1984, 128(24):1150-1152.
4. van der Heijden O.G., et al. A model-based evaluation of the national immunization programme against rubella infection and congenital rubella syndrome in The Netherlands. Epidemiol Infect 1998, 121(3):653-671.
5. van Lier E.A., et al. Immunization coverage National Immunization Programme in The Netherlands. RIVM Rapport 150202001/2013 2013.
6. Nokes D.J., Anderson R.M. Measles, mumps, and rubella vaccine: what coverage to block transmission?. Lancet 1988, 2(8624):1374.
7. Hahne S., et al. Rubella outbreak in The Netherlands, 2004-2005: high burden of congenital infection and spread to Canada. Pediatr Infect Dis J 2009, 28(9):795-800.
8. Ruijs W.L., et al. Measuring vaccination coverage in a hard to reach minority. Eur J Public Health 2012, 22(3):359-364.
9. De Melker H.E., Conyn-van Spaendonck M.A. Immunosurveillance and the evaluation of national immunization programmes: a population-based approach. Epidemiol Infect 1998, 121(3):637-643.
10. van der Klis F.R., et al. Second national serum bank for population-based seroprevalence studies in The Netherlands. Neth J Med 2009, 67(7):301-308.
11. Steens A., et al. High tetanus antitoxin antibody concentrations in The Netherlands: a seroepidemiological study. Vaccine 2010, 28(49):7803-7809.
12. Smits G.P., et al. Development of a bead-based multiplex immunoassay for the simultaneously quantitative detection of IgG serum antibodies against measles, mumps, rubella and varicella zoster. Clin Vaccine Immunol 2012, 19(3):396-400.
13. Andrews N., et al. The European Sero-Epidemiology Network: standardizing the enzyme immunoassay results for measles, mumps and rubella. Epidemiol Infect 2000, 125(1):127-141.
14. Team, T.R.D.C. R: A language and environment for statistical computing 2011, R Foundation for Statistical Computing, Vienna, Austria.
15. Bickel P.J., Doksum K.A. Basic heuristics of estimation. Mathematical statistics: basic ideas and selected topics 2001, 101. Prentice-Hall, London. P.J. Bickel, K.A. Doksum (Eds.).
16. de Haas R., et al. Prevalence of antibodies against rubella virus in The Netherlands 9 years after changing from selective to mass vaccination. Epidemiol Infect 1999, 123(2):263-270.
17. Christenson B., Bottiger M. Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults. Vaccine 1994, 12(1):41-45.
18. Peltola H., et al. The elimination of indigenous measles: mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 1994, 331(21):1397-1402.
19. Vandermeulen C., et al. Long-term persistence of antibodies after one or two doses of MMR-vaccine. Vaccine 2007, 25(37-38):6672-6676.
20. Horstmann D.M., et al. Persistence of vaccine-induced immune responses to rubella: comparison with natural infection. Rev Infect Dis 1985, 7(Suppl 1):S80-S85.
21. Mossong J., Putz L., Schneider F. Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: results from a national cross-sectional study. Epidemiol Infect 2004, 132(1):11-18.
22. Amanna I.J., Carlson N.E., Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007, 357(19):1903-1915.
23. Kontio M., et al. Waning antibody levels and avidity: implications for MMR vaccine-induced protection. J Infect Dis 2012, 206(10):1542-1548.
24. http://www.rivm.nl/Documenten_en_publicaties/Algemeen_Actueel/Nieuwsberichten/2013/Start_extra_vaccinatie_tegen_mazelen Accessed again on 12-02-2014.